New study seeks answers for Women's Post-Transplant health problems
NCT ID NCT06279676
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 100 women who have had a stem cell transplant to better understand a condition called vulvovaginal chronic graft-versus-host disease (cGVHD). Researchers want to learn how common it is, what symptoms look like, and how it affects sexual health. The goal is to help doctors give better care to future patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better guidelines for managing gynecological health in women after stem cell transplants.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not directly improve health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2024
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Allotransplanted women who receive a first allogeneic stem cell transplant.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All women aged 18 and over who will receive a first allogeneic HSCT (bone marrow, peripheral blood stem cells from a related, unrelated (including cord blood) or haploidentical donor) at the CIUSSS-EMTL. Recruitment will begin when the project receives ethical approval. Recruitment period will be of 2 to 3 years. Exclusion Criteria: 1. Those who receive a second HSCT allograft. 2. Those who receive an autologous transplant. 3. Inability to give informed consent. 4. Unable to communicate in French or English. 5. Any other reason which, according to the investigators, makes it preferable for a patient not to participate.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD, chronic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CIUSSS de l'Est-de-l'Ile-de-Montréal / Hôpital Maisonneuve-Rosemont
RECRUITINGMontreal, Quebec, H1T 2M4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.